Γ—

Benefits of Dasatinib and Quercetin Treatment in Monkeys

Positive effects were reported in the kidneys, intestines, and whole body.

Share







MacaquesMacaques

In one of the first studies of its kind, the popular senolytic combination, administered systematically for six months, produced several health benefits in these animals. Some effects were augmented by caloric restriction [1].

Coup de grΓ’ce for cells

The combination of the drug dasatinib and the flavonoid quercetin, also known as D+Q, is one of the most popular senolytics (compounds that induce death in senescent cells). It has been the subject of numerous preclinical and some clinical trials, showing a lot of promise [2]. However, there is limited data on safety and efficacy of long-term systemic administration of D+Q in humans or humanlike animal models.

This new study attempts to fill the gap. The scientists treated 16 middle-aged cynomolgus macaques, males and females, with D+Q for six months. The drug was administered orally for two consecutive days once per month. For the last month, the animals were also subjected to mild caloric restriction (10%) to reveal any potential synergistic effects, as caloric restriction itself is a powerful anti-aging therapy [3].

Reduced senescence

As expected, the treatment led to a significant reduction in cellular senescence that was measured in subcutaneous tissue three months after the beginning of the experiment. In parallel, the markers of apoptosis (cellular death) increased, indicating effective senolysis.

D and Q in monkeys

Interestingly, three diabetic monkeys were included in each group. In the study group, they showed the greatest senolysis, about three times more than their non-diabetic counterparts. While the number of diabetic subjects was too low for statistical analysis, the trend suggests that diabetic individuals might benefit more from a senolytic treatment.

Less inflammation and other benefits

The D+Q treatment also produced some anti-inflammatory effects, with significant or borderline significant shifts in blood cell composition. Caloric restriction further reduced inflammation, and a mild synergy was observed between the two treatments. The researchers hypothesize that somewhat ambiguous results might be explained by the activity of macrophages clearing away dying senescent cells.

One of the highly conserved features of aging is the degradation of the intestinal barrier, which leads to microbial and other pathogens entering the bloodstream. The D+Q treatment led to a significant improvement in markers of intestinal barrier integrity. This effect was augmented by caloric restriction. No significant changes in microbiome composition were observed.

Kidney function seemed to benefit from the senolytic treatment as well. Blood urea nitrogen (BUN), a common marker of kidney health, was significantly improved. This time, however, caloric restriction did not add any benefits.

On the metabolic front, D+Q by themselves failed to produce any significant benefits, although there was a trend towards a lower abdominal to subcutaneous fat ratio; abdominal fat is thought to be more unhealthy. Caloric restriction, on the other hand, expectedly shined, with highly significant reductions in body weight, waist circumference, and increased percentage of lean mass. It also reduced triglycerides and fasting blood glucose. However, an interesting synergistic effect between the two treatments was observed in improving hemoglobin A1C (HbA1c), an important metric of average glucose levels over a time period.

Given the outcomes of this study, we believe that these data provide preliminary evidence to support safe implementation of a human clinical trial, perhaps focused on diabetic kidney disease in mid-to-late-age adults. We believe that intermittent D + Q combined with low-percentage caloric restriction would signifcantly and safely ameliorate infammation, glycemia and renal outcomes associated with metabolic dysfunction related to aging.

While this study did not lead to dramatic outcomes, it demonstrated the feasibility and safety of systemic administration of D+Q over a period of time relevant for human clinical trials. It also led to additional benefits besides lower senescent cell burden, such as lower inflammation. Finally, it showed an intriguing synergy between a senolytic treatment and reasonably manageable caloric restriction that is worth exploring further.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Developing a Treatment for Arthritis from Stem Cell Signals

Resarchers publishing in Aging have found that extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells (MSCs) reduce...

Creating a Noise Clock to Measure Biological Age

Publishing in Aging, the Conboy research lab has outlined the problems with existing machine learning-based clocks and created a new...

EARD2023: Using NFTs to Support Video Gaming for Good

In this talk, Lifespan.io President Keith Comito describes use cases for "Proof of Philanthropy" (PoP) dynamic NFTs - a new...

Senolytics as a Potential Back Pain Treatment

In a recent paper, researchers from McGill University in Canada have investigated how a combination of two senolytics, RG-7112 and...

Literature

[1] Ruggiero, A.D., Vemuri, R., Blawas, M. et al. (2023). Long-term dasatinib plus quercetin effects on aging outcomes and inflammation in nonhuman primates: implications for senolytic clinical trial design. GeroScience.

[2] Hickson, L. J., Prata, L. G. L., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., … & Kirkland, J. L. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine, 47, 446-456.

[3] Masoro, E. J. (2005). Overview of caloric restriction and ageing. Mechanisms of ageing and development, 126(9), 913-922.

About the author
Arkadi Mazin

Arkadi Mazin

Arkadi is a seasoned journalist and op-ed author with a passion for learning and exploration. His interests span from politics to science and philosophy. Having studied economics and international relations, he is particularly interested in the social aspects of longevity and life extension. He strongly believes that life extension is an achievable and noble goal that has yet to take its rightful place on the very top of our civilization’s agenda – a situation he is eager to change.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.